Chimerix Inc. released its end of the year report on the development of antiviral medicines, specifically the testing process of its brincidofovir (BCV) Ebola treatment candidate, on Tuesday.
The company is involved in the development of antivirals that are taken orally that aim to meet current vacancies in available medical treatment.
Chimerix'sr BCV candidate entered AdVise testing in March for the treatment of life-threatening infections from the adenovirus in children. The adenovirus causes several types of illnesses including colds, bronchitis and pneumonia. A separate study conducted by the U.S. Centers for Disease Control and Prevention indicated that BCV could be a viable candidate in treating the Ebola virus.
"Through the last few months, Chimerix has partnered with global health organizations and government agencies to advance the critical clinical studies which will help us understand the potential role of brincidofovir in treating Ebola virus disease, and in treating or preventing multiple life-threatening viral infections in at-risk patients," Chimerix President and CEO Dr. M. Michelle Berrey said. "Chimerix is now poised to deliver on significant corporate and development milestones in 2015."
Additional results from the AdVise study on BCV intreating adenovirus are expected in 2015. Clinical testing of the compound's capability to treat Ebola will begin in 2015 in Liberia.
Results from a study involving 450 patients that were treated with BCV for cytomegalovirus infections are set to be released in the second half of 2015. If the results look promising, it would facilitate the first regulatory submission for the compound's use to treat potential complications from stem cell transplants.